ProCE Banner Activity

SOLO3: Phase III Trial of Olaparib vs Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and Germline BRCA Mutation

Slideset Download
Conference Coverage
Olaparib treatment was associated with significant improvements in ORR and PFS vs nonplatinum chemotherapy for patients with platinum-sensitive relapsed ovarian cancer and germline BRCA mutation.

Released: June 11, 2019

Expiration: June 09, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro